Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy

Table 4 Resistance associated mutations and cross-resistance to approved and advanced phase-studied NS3/4 protease inhibitors

Drug	Molecule	V36A/M	F43S	T54S/A	V55A/K	Q80R/K	S122A/G/R	I132V	R155K/T/Q	A156S/D/T/V	V158I	D168A/V/T/H	I170F/T1V170A/T1	M175L
Telaprevir	Linear	-2		-2				-3	-2	-2		-3
Boceprevir	Linear	-2		-2	-2				-2	-2	-3		-3	-3
Faldaprevir	Linear								-2	-3		-2	-3
Danoprevir	Macrocyclic					-3			-2			-2	-3
Vaniprevir	Macrocyclic		-3						-2	-3		-2
Simeprevir	Macrocyclic					-2	-3		-2	-3		-2

¹The I170F/T and the V170A/T mutations were detected in hepatitis C virus genotype 1a and 1b, respectively, in which I and V represent the consensus amino acid, respectively;

²Indicates resistance associated mutations detected in virologically failed patients and confirmed by phenotypic tests;

³Indicates mutations detected as additional mutations or still of uncertain significance.